12.53

3.84% -0.50

Tonix Pharmaceuticals Holding Corp (TNXP)

Panoramica Notizia Cronologia dei prezzi Financials Perché TNXP Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$13.03

Aprire:

$13.07

Volume 24 ore:

504.87K

Relative Volume:

1.04

Capitalizzazione di mercato:

$199.74M

Reddito:

$13.11M

Utile/perdita netta:

$-124.02M

Rapporto P/E:

-0.8786

EPS:

-14.261

Flusso di cassa netto:

$-107.25M

1 W Prestazione:

+1.54%

1M Prestazione:

+14.32%

6M Prestazione:

-19.06%

1 anno Prestazione:

-70.42%

Intervallo 1D:

$12.36

$13.15

Intervallo di 1 settimana:

$12.10

$13.19

Portata 52W:

$10.03

$69.97

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile

Nome

Tonix Pharmaceuticals Holding Corp

Settore

Healthcare (1096)

Industria

Biotechnology (616)

Telefono

212-980-9155

Indirizzo

200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY

Dipendente

142

Cinguettio

@TONIXPharma

Prossima data di guadagno

2026-08-10

Ultimi documenti SEC

TNXP's Discussions on Twitter

Compare TNXP vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TNXP Tonix Pharmaceuticals Holding Corp	12.53	199.74M	13.11M	-124.02M	-107.25M	-14.26
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2022-04-18	Iniziato	Noble Capital Markets	Outperform
2019-04-18	Aggiornamento	ROTH Capital	Neutral → Buy
2017-08-18	Aggiornamento	ROTH Capital	Neutral → Buy
2016-09-07	Downgrade	ROTH Capital	Buy → Neutral
2016-02-17	Reiterato	Oppenheimer	Outperform
2015-11-04	Iniziato	Cantor Fitzgerald	Buy
2015-06-12	Iniziato	Oppenheimer	Outperform
2015-02-17	Reiterato	ROTH Capital	Buy
2014-09-29	Reiterato	ROTH Capital	Buy

Mostra tutto

Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie

Jul 11, 2026

TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug - Stocktwits

Jul 11, 2026

Jul 10, 2026

Why TNXP Stock Is Suddenly Back On Retail Radar - Stocktwits

Jul 10, 2026

Jul 09, 2026

Tonix Pharmaceuticals (TNXP) Investor presentation Summary - Quartr

Jul 09, 2026

Form 4 Tonix Pharmaceuticals Holding Corp For: 9 July By Investing.com - Investing.com Nigeria

Jul 09, 2026

Tonix (NASDAQ: TNXP) CFO adds 1,453 shares through 2025 employee stock plan - Stock Titan

Jul 09, 2026

Jul 06, 2026

TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits

Jul 06, 2026

Jul 02, 2026

Technical Reactions to TNXP Trends in Macro Strategies - Stock Traders Daily

Jul 02, 2026

Jun 30, 2026

Tonix: 'Hold' Based On Tonmya Payer Expansions And MDD Trial Initiation - Seeking Alpha

Jun 30, 2026

Jun 29, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 29, 2026

Tonix Pharmaceuticals Holding Corp. has enrolled the first patient in its Phase 2 “HORIZON” study of TNX-102 SL (sublingual tablet) for the treatment of major depressive disorder (MDD). - Bitget

Jun 29, 2026

Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating (NASDAQ:TNXP) - Seeking Alpha

Jun 29, 2026

Tonix enrolls first patient in Phase 2 depression study - grafa.com

Jun 29, 2026

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD) - The Manila Times

Jun 29, 2026

Tonix Pharma Begins Pivotal Phase 2 Depression Trial - TipRanks

Jun 29, 2026

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for Major Depressive Disorder - Quiver Quantitative

Jun 29, 2026

Tonix Pharmaceuticals Announces First Patient Enrolled in - GlobeNewswire

Jun 29, 2026

Tonix starts Phase 2 depression trial for TNX-102 SL - Stock Titan

Jun 29, 2026

Jun 26, 2026

Tonix Pharmaceuticals Holding Corp. Actuals & Estimates (DUS:TPM0) - TradingView

Jun 26, 2026

Enterprise value to revenue forward of Tonix Pharmaceuticals Holding Corp. – NASDAQ:TNXP - TradingView

Jun 26, 2026

Tonix Pharmaceuticals Holding Corp. Actuals & Estimates (NASDAQ:TNXP) - TradingView

Jun 26, 2026

Jun 25, 2026

Tonix Pharmaceuticals Holding Corp. Actuals & Estimates (FWB:TPM0) - TradingView

Jun 25, 2026

Enterprise value to EBIT forward of Tonix Pharmaceuticals Holding Corp. – NASDAQ:TNXP - TradingView

Jun 25, 2026

Price to sales forward of Tonix Pharmaceuticals Holding Corp. – NASDAQ:TNXP - TradingView

Jun 25, 2026

Enterprise value to EBITDA forward of Tonix Pharmaceuticals Holding Corp. – NASDAQ:TNXP - TradingView

Jun 25, 2026

Tonix Pharmaceuticals (TNXP) Receives Strong Buy Rating with $26 Target - GuruFocus

Jun 25, 2026

TNXP Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

TNXP Initiated Coverage by Raymond James -- Price Target Set at $26 - GuruFocus

Jun 25, 2026

Jun 24, 2026

Raymond James initiates Tonix Pharma stock coverage with strong buy By Investing.com - Investing.com South Africa

Jun 24, 2026

Raymond James initiates Tonix Pharma stock coverage with strong buy - Investing.com

Jun 24, 2026

TNXP Stock Rises Premarket: Investors Cheer Early Traction For Fibromyalgia Drug Despite Weak Q4 Print - Stocktwits

Jun 24, 2026

Jun 22, 2026